Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients

European Institute of Oncology

Status and phase: Completed; Phase 4

Conditions: Cardiotoxicity; Chemotherapeutic Toxicity

Treatments: Drug: Enalapril

Study type: Interventional

Funder types: Other

Identifiers

NCT00292526

IEO S67/500

Details and patient eligibility

About

In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.

Enrollment: 114 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Consecutive patients undergoing high-dose chemotherapy showing early release of Troponin I

Exclusion criteria

• Contraindication to ACE-inhibitors
• On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

114 participants in 1 patient group

enalapril arm

Experimental group

Description:

treatment with enalapril

Treatment:

Drug: Enalapril